Lindis Biotech GmbH, a clinical stage bio-pharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, was founded in 2010 by Dr. Horst Lindhofer, inventor of the Triomab® platform. Lindis Biotech is the only company that owns a technology which combines extremely effective tumor cell destruction with a patient-specific vaccination based on trifunctional bispecific antibodies. The Company is therefore ideally positioned in the area of cancer immunotherapeutic agents. As the first product to emerge from this platform and a breakthrough in the development of bispecific antibodies, CATUMAXOMAB was approved in 2009 in Europe under the name Removab® for the indication of malignant ascites and has proven its safety and anti-tumor efficacy in the clinic.